SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-031826
Filing Date
2023-09-06
Accepted
2023-09-06 16:15:32
Documents
57
Period of Report
2023-07-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 759001
2 ex31-1.htm EX-31.1 18104
3 ex31-2.htm EX-31.2 20318
4 ex32-1.htm EX-32.1 7289
5 ex32-2.htm EX-32.2 8421
  Complete submission text file 0001493152-23-031826.txt   4077926

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE anix-20230731.xsd EX-101.SCH 29421
7 XBRL CALCULATION FILE anix-20230731_cal.xml EX-101.CAL 40643
8 XBRL DEFINITION FILE anix-20230731_def.xml EX-101.DEF 138214
9 XBRL LABEL FILE anix-20230731_lab.xml EX-101.LAB 258896
10 XBRL PRESENTATION FILE anix-20230731_pre.xml EX-101.PRE 203915
51 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 608817
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 231239355
SIC: 2834 Pharmaceutical Preparations